About us
about us
New approaches to the respiratory diseases
Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections.
Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses.
Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive molecular diagnostics. BreathForDx’s overall goal is to tackle this problem by establishing exhaled breath aerosol (XBA) as a novel, evidence-based sample for respiratory infections in three use cases: diagnosis, screening, and antimicrobial resistance, using tuberculosis as a model infection.
breath for dx concept
The BreathForDx project will demonstrate the potential of XBA as a new sample for airborne pathogens through seven interconnected work packages. They will cover the pathway from optimisation of the AveloCollect device to impact assessment of both AveloCollect and FMS devices. Three prospective clinical studies will run in parallel. Lastly, an assessment of feasibility of implementation across different settings at scale, cost-effectiveness, and population-level impact will be performed.
Breath for DX
New approches to breath diseases
Current diagnostic methods for respiratory infections, such as swab sampling and sputum collection, are flawed due to discomfort, sampling errors, and limitations in pathogen detection. Molecular diagnostics have advanced, enabling ultra-sensitive pathogen detection near patients, but sampling techniques remain a bottleneck.
